Latest Breaking News On - Site directed enzyme enhancement therapy - Page 5 : comparemela.com

Critical Analysis: Acurx Pharmaceuticals (NASDAQ:ACXP) and Gain Therapeutics (NASDAQ:GANX)

Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) and Gain Therapeutics (NASDAQ:GANX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations. Institutional & Insider Ownership 11.3% of Acurx […]

Staten islandNew yorkUnited statesNews ratings for acurx pharmaceuticals dailyAcurx pharmaceuticals incGain therapeutics incAcurx pharmaceuticalsGet free reportGain therapeuticsGiven gain therapeuticGain therapeuticSite directed enzyme enhancement therapyAcurx pharmaceuticals dailyNasdaq acxpStock comparisonStock analysis

Gain Therapeutics, Inc Expected to Post Q1 2024 Earnings of ($0 46) Per Share (NASDAQ:GANX)

Gain Therapeutics, Inc Expected to Post Q1 2024 Earnings of ($0 46) Per Share (NASDAQ:GANX)
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United kingdom generalUnited kingdomGain therapeutics incDimensional fund advisorsGain therapeutics company profileNewedge advisorsSusquehanna international groupBlackrock incGain therapeuticsFree reportGain therapeuticChardan capitalEdge advisorsStreet groupFund advisorsInternational group

Gain Therapeutics, Inc (NASDAQ:GANX) Sees Large Decrease in Short Interest

Gain Therapeutics, Inc (NASDAQ:GANX) Sees Large Decrease in Short Interest
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Renaissance technologiesNewedge advisorsDimensional fund advisorsGain therapeutics incRoyal bankGain therapeuticsGet free reportStreet groupFund advisorsSite directed enzyme enhancement therapyGain therapeutics daily

Gain Therapeutics, Inc (NASDAQ:GANX) Expected to Post Q4 2023 Earnings of ($0 28) Per Share

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) – HC Wainwright lifted their Q4 2023 EPS estimates for Gain Therapeutics in a research report issued to clients and investors on Monday, May 15th. HC Wainwright analyst B. Pachaiyappan now anticipates that the company will earn ($0.28) per share for the quarter, up from their previous estimate […]

Renaissance technologiesSusquehanna international groupRoyal bankGain therapeutics incRaymond james associatesDimensional fund advisorsGain therapeuticsGet ratingGain therapeuticChardan capitalInternational groupSite directed enzyme enhancement therapyGain therapeutics dailyNasdaq ganxEarnings estimatesHc wainwright

Gain Therapeutics, Inc (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 59,800 shares, a decline of 7.1% from the April 15th total of 64,400 shares. Based on an average daily volume of 79,300 shares, the days-to-cover ratio is […]

Raymond james associatesGain therapeutics incDimensional fund advisorsGain therapeutics company profileNewedge advisorsSusquehanna international groupGain therapeuticsGet ratingChardan capitalEdge advisorsStreet groupFund advisorsInternational groupRaymond jamesSite directed enzyme enhancement therapyGain therapeutics daily